Top Abstracts To Watch: ASH 2020

These research results will have impact in 2021

The American Society of Hematology’s (ASH) annual meeting is an excellent opportunity to discover and discuss the latest developments in the treatment of blood disorders and malignancies. The staff of Cleveland Clinic Cancer Center’s Department of Hematology and Medical Oncology has chosen these abstracts presented at ASH 2020 as the most compelling, clinically relevant and potentially practice-changing that included research from our clinical team.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

  1. 34 The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia
  2. 257 Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia
  3. 408 The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH
  4. 438 Abnormal Metaphase Cytogenetics Adds to Currently Known Risk-Factors for Venous Thromboembolism in Multiple Myeloma: Derivation of the PRISM score
  5. 516 Thromboembolism in Patients with Advanced Renal Cell Carcinoma Treated with Immunotherapy
  6. 541 A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes
  7. 655 Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)
  8. 729 Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis
  9. 762 Identification of a Warm Autoimmune Hemolytic Anemia (wAIHA) Population Using Predictive Analytics of a Known Clinically Profiled Cohort
  10. 1447 Unbiased Metabolomic Screening Reveals Pre-Existing Plasma Signatures in Large B-Cell Lymphoma Patients Treated with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cells: Association with Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS)